Drugs & Targets FDA grants Fast Track designation to IK-930 in unresectable NF2-deficient mesothelioma June 24, 2022Vol.48 No.25
Drugs & Targets Cullinan Oncology, Taiho Pharmaceuticals complete agreement to develop and commercialize CLN-081/TAS6417 June 24, 2022Vol.48 No.25
Drugs & Targets SomaLogic, OncoHost announce license agreement for the development of precision cancer diagnostics June 17, 2022Vol.48 No.24
Drugs & Targets MD Anderson, Invectys, CTMC announce strategic collaboration for CAR T-cell therapy development June 17, 2022Vol.48 No.24
Drugs & Targets Parker Institute for Cancer Immunotherapy, Resilience partner to develop cell and gene therapies June 10, 2022Vol.48 No.23
Drugs & Targets Dana-Farber, Gustave Roussy, L’Institut Servier sign oncology cooperation agreement June 10, 2022Vol.48 No.23
Drugs & Targets FDA campaign aims to prevent e-cigarette use among AI/AN youth June 10, 2022Vol.48 No.23
Drugs & Targets FDA approves two Opdivo-based regimens in unresectable advanced or metastatic ESCC June 03, 2022Vol.48 No.22
